HOUSTON--(BUSINESS WIRE)--Kuur Therapeutics, the leading developer of off-the-shelf CAR-NKT cell immunotherapies for the treatment of solid and hematological malignancies, today announced clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results